Coherus Biosciences Inc  

(Public, NASDAQ:CHRS)   Watch this stock  
Find more results for CHRS
24.98
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 12.27 - 33.30
Open     -
Vol / Avg. 0.00/245,530.00
Mkt cap 945.28M
P/E     -
Div/yield     -
EPS -5.79
Shares 37.84M
Beta     -
Inst. own 35%
May 11, 2015
Q1 2015 Coherus BioSciences Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 Coherus BioSciences Inc Earnings Release
May 7, 2015
Coherus BioSciences Inc at Deutsche Bank Health Care Conference - Webcast
Mar 23, 2015
Q4 2014 Coherus BioSciences Inc Earnings Call - Webcast
Mar 23, 2015
Q4 2014 Coherus BioSciences Inc Earnings Release
Mar 2, 2015
Coherus Biosciences Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -702.91% -280.26%
Operating margin -632.50% -207.94%
EBITD margin - -205.77%
Return on average assets -96.25% -74.30%
Return on average equity -311.28% -
Employees 66 -
CDP Score - -

Address

201 Redwood Shores Pkwy Ste 200
REDWOOD CITY, CA 94065-1181
United States - Map
+1-650-6493530 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Coherus BioSciences Inc. (Coherus) is a late-stage clinical biologics platform Company. The Company is focused on delivering biosimilar therapeutics. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. The Company has worked on approximately 100 molecules, developed and manufactured around 14 products and launched approximately 30 products across the world. Coherus’ is in partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Officers and directors

Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Jean-Frederic Viret Ph.D. Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Peter K. Watler Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Alan C. Herman Ph.D. Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
Barbara K. Finck M.D. Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Christos Richards Director
Age: 57
Bio & Compensation  - Reuters
August J. Troendle M.D. Director
Age: 58
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Ali J. Satvat Independent Director
Age: 37
Bio & Compensation  - Reuters